Bioniche Life Sciences Inc. 25 Years
Contact Us Careers
Home Newsroom
In the News

September 16, 2014
Bioniche Files Final Prospectus For Equity Offering

August 22, 2014
Bioniche Life Sciences Announces Terms of $5 Million Financing & Use of Proceeds

Investors

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.


Newsroom

All Releases

September 2014

16/09/14
Bioniche Files Final Prospectus For Equity Offering

August 2014

22/08/14
Bioniche Life Sciences Announces Terms of $5 Million Financing & Use of Proceeds

21/08/14
Bioniche Life Sciences Announces Overnight Marketed Offering

19/08/14
Bioniche Announces Q1/2015 Timeline for the Filing of a Biologics License Application for Marketing Approval of MCNA in the United States

July 2014

29/07/14
Bioniche Announces Submission of Orphan Drug Designation Application for MCNA in the United States

18/07/14
Bioniche Announces Intention to File for Marketing Approval of MCNA in the United States

June 2014

13/06/14
Bioniche Life Sciences Inc. to Present at Bloom Burton & Co. Healthcare Investor Conference

03/06/14
Bioniche Provides Corporate Update

May 2014

14/05/14
Bioniche Life Sciences Inc. Reports Fiscal 2014 Third Quarter Results

April 2014

15/04/14
Vétoquinol and Bioniche Life Sciences Inc. Close Sale of Bioniche Animal Health Business

14/04/14
Bioniche Life Sciences Inc. Shareholders Approve Sale of Animal Health Business

03/04/14
ISS Recommends that Bioniche Shareholders Vote in Favour of Animal Health Sale Transaction

03/04/14
Bioniche Life Sciences Inc. Continues to Execute on Strategic Review

March 2014

13/03/14
Bioniche Life Sciences Inc. Holds Shareholder Conference Call/Webcast

04/03/14
Bioniche Life Sciences Inc. Announces Key Corporate Updates

February 2014

26/02/14
Vétoquinol to Acquire the Animal Health Business of Bioniche Life Sciences Inc.

06/02/14
Bioniche Life Sciences Inc. Reports Fiscal 2014 Second Quarter Results and Announces Strategic Expenditure Review and New One Health Strategy

January 2014

07/01/14
Bioniche Life Sciences Inc. Appoints a Chief Operating Officer

December 2013

11/12/13
Bioniche Life Sciences Inc. Delisting Approved by the ASX

04/12/13
Primary and Long-Term Illness Related to E. coli O157 Costs $403.9 Million per Year in Canada

02/12/13
Bioniche Life Sciences Inc. Horse Product Approved for Sale in the U.S.

November 2013

07/11/13
Bioniche Life Sciences Inc. Reports Fiscal 2014 First Quarter Results

04/11/13
Bioniche Life Sciences Inc. Announces the Appointment of a New Chief Executive Officer

October 2013

18/10/13
Bioniche Management Proxy Circular for 2013 Annual and Special Meeting Now Available

07/10/13
Bioniche Provides an Update on Plans for a New Drug Submission Filing in Canada

September 2013

27/09/13
Bioniche Life Sciences Inc. Reports Fiscal 2013 Year-End Results

26/09/13
Bioniche Closes Canadian Equity Offering and Related Private Placement

18/09/13
Bioniche Files Final Prospectus for Canadian Equity Offering

12/09/13
Bioniche Life Sciences Inc. and Concerned Shareholders Announce a Settlement

11/09/13
Bioniche Founder and CEO Announces his New Role with the Company

August 2013

07/08/13
Bioniche Confirms Pricing of Canadian Equity Offering

06/08/13
Bioniche Files Preliminary Prospectus for Canadian Equity Offering

July 2013

23/07/13
Ontario Court Confirms Timing of Bioniche’s Annual Meeting of Shareholders

15/07/13
Bioniche's Lead Animal Health Product Gains Access to Seven Additional European Markets

08/07/13
Health Canada Provides Direction to Bioniche Life Sciences Inc. Regarding New Drug Submission Filing

05/07/13
Paladin Labs Inc. and Bioniche Life Sciences Inc. Officially Close Debt Refinancing and Urocidin™ Licensing Deals

June 2013

28/06/13
Bioniche Responds to Dissident Shareholders' Latest Tactics

27/06/13
Bioniche Life Sciences Inc. to Provide an Update on Vaccine Manufacturing Centre Validation

12/06/13
Bioniche Founder and CEO Addresses Shareholders

05/06/13
Paladin Labs Inc. and Bioniche Life Sciences Inc. Sign Debt Refinancing and Urocidin™ Licensing Deals

May 2013

29/05/13
Bioniche Responds to Dissident Shareholders and Rejects Call for Early Shareholder Meeting

13/05/13
Bioniche Engages Evercore Partners to Assist in the Divestment of its Animal Health Business

08/05/13
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2013 Results

04/05/13
Bioniche Life Sciences Inc. Responds to Dissident Request for Shareholder Meeting

April 2013

26/04/13
Bioniche Life Sciences Inc. Acknowledges Request for Shareholder Meeting

22/04/13
Bioniche Life Sciences Inc. Responds to Letter from Former Biovail Executives

19/04/13
Bioniche Life Sciences Inc. Experiences Increased Trading Activity

18/04/13
Bioniche E. coli O157 Vaccine to be Used in an On-Farm Intervention Study in Sweden

01/04/13
Bioniche Life Sciences Inc. Regains Sponsorship of Urocidin™

March 2013

27/03/13
Bioniche Life Sciences Inc. Receives Government of Canada Support for Second Generation E. coli O157 Vaccine

26/03/13
Bioniche Life Sciences Inc. Reacts to Canadian Federal Budget

07/03/13
Bioniche Life Sciences Inc. Reorganizes One of its Business Units

February 2013

28/02/13
Vaccination of Cattle to Reduce Public Health Risk of E. coli O157 Featured in the Canadian Journal of Public Health

06/02/13
Bioniche Life Sciences Inc. Reports Q2, Fiscal 2013 Results

January 2013

30/01/13
Bioniche Life Sciences Inc. Terminates its License Agreement with Trophogen Inc.

24/01/13
Bioniche Life Sciences Inc. Launches Two New Animal Health Products in Canada

03/01/13
Bioniche Life Sciences Inc. Provides an Update on the Return of Urocidin™ Global Rights

December 2012

21/12/12
Endo Pharmaceuticals Returns Urocidin™ Global Rights to Bioniche Life Sciences Inc.

13/12/12
Bioniche Life Sciences Inc. Achieves Registration of Enhance™ I.A./I.V. in Hong Kong

06/12/12
Bioniche Life Sciences Inc. Announces a Change to its Board of Directors

04/12/12
Bioniche Life Sciences Inc. Launches NexHA™ in Canada

November 2012

21/11/12
U.S. Distributor Appointed for Bioniche’s ImmunocidinTM Canine Oncology Therapy

07/11/12
Bioniche Life Sciences Inc. Reports Q1, Fiscal 2013 Results

05/11/12
Bioniche Life Sciences Inc. Announces Discontinuation of Current Phase III Clinical Trial with Urocidin™

October 2012

17/10/12
Bioniche Life Sciences Inc. Announces North American Market Launch of ImmunocidinTM

September 2012

20/09/12
Bioniche Life Sciences Inc. Discovers a Counterfeit Equine Product

12/09/12
Bioniche Life Sciences Inc. Reports Fiscal 2012 Year-End Results

August 2012

20/08/12
Bioniche Launches New U.S. Equine Product and Acquires Canadian Distribution Rights to Six Additional Products

13/08/12
Bioniche Life Sciences Inc. Enters into an Exclusive U.S. Distribution Agreement for an Equine Product

07/08/12
Special Treatment Certificate Issued for Importation of E. coli O157 Vaccine into the United Kingdom

July 2012

31/07/12
Bioniche Presents Preliminary Data on the Use of In-Licensed Superagonist Hormone Technology in Cattle

30/07/12
Bioniche Life Sciences Inc. Appoints an Independent Chairman of its Board of Directors

23/07/12
Bioniche Life Sciences Inc. Moves Closer to Market Launch of ImmunocidinTM

May 2012

28/05/12
Most Effective Strategy for Managing E. coli O157:H7 in Beef is a Combination of a Pre-Harvest Intervention and Several Processing Interventions

09/05/12
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2012 Results

01/05/12
Bioniche Life Sciences Inc. Commercializing Two Products for Canine Cancer

April 2012

18/04/12
Bioniche Life Sciences Inc. Sponsors Two Major International Livestock Reproduction Conferences

11/04/12
Bioniche Life Sciences Inc. Closes US$20M Financing from Capital Royalty L.P.

March 2012

23/03/12
Bioniche Life Sciences Inc. Enters into a Distribution Agreement for New Animal Health Products in Australia

19/03/12
Bioniche Life Sciences Inc. Accepts US$20M Financing Offer from Capital Royalty L.P.

February 2012

09/02/12
Bioniche Life Sciences Inc. Reports Q2, Fiscal 2012 Results

09/02/12
Bioniche Life Sciences Inc. Q2, Fiscal 2012 Conference Call and Audio Webcast

December 2011

21/12/11
Bioniche Life Sciences Inc. Enters into Two Distribution Agreements for New Animal Health Products

13/12/11
Bioniche E. coli Vaccine Granted Import Access to Australia

12/12/11
Bioniche Life Sciences Inc. Reports Q1, Fiscal 2012 Results

November 2011

15/11/11
Bioniche Life Sciences Inc. Congratulates Dr. Alvaro Morales on his Appointment as Member of the Order of Canada

09/11/11
Bioniche Life Sciences Inc. Holds Annual & Special Meeting of Shareholders

October 2011

27/10/11
Bioniche Life Sciences Inc. Receives Canadian Regulatory Approval for Equine Anti-Inflammatory Product

20/10/11
New York Court Grants Summary Judgment in Favour of Bioniche Life Sciences Inc.

September 2011

29/09/11
Bioniche Life Sciences Inc. Launches Three New Products

22/09/11
Bioniche Life Sciences Inc. Outlines Plan to Achieve Profitability

15/09/11
Bioniche Reports Fiscal 2011 Year-End Results

August 2011

01/08/11
Bioniche Life Sciences Inc. Will Not Proceed With Business and Asset Acquisition of Plasvacc Holdings Limited

July 2011

04/07/11
Bioniche Life Sciences Inc. has Agreed to Acquire Plasvacc Holdings Limited of Australia

June 2011

13/06/11
Bioniche Chief Veterinary Scientific Officer Discusses Vaccine Against E. coli O157 at International Meat Industry Conference

May 2011

17/05/11
Urocidin™ Phase III Clinical Trial Results Presented at AUA Conference in Washington, D.C.

11/05/11
Bioniche Life Sciences Inc. Reports Fiscal 2011 Third Quarter Results

05/05/11
Econiche™ Vaccine Efficacy Challenge Study Summarized in The Canadian Journal of Veterinary Research

April 2011

29/04/11
Animal Health and Food Safety Vaccine Manufacturing Centre Officially Opens in Belleville, Ontario, Canada

March 2011

31/03/11
Folltropin®-V - a Key Bioniche Animal Health Product - Receives Marketing Authorization in China

22/03/11
Bioniche Life Sciences Inc. Keynote Speaker at 7th Annual NZBIO Conference in New Zealand

February 2011

18/02/11
Urocidin™ Phase III Clinical Trial Results To Be Presented At EAU and AUA Conferences

17/02/11
First Patient Enrolled In Second Phase III Clinical Trial Of Urocidin™

15/02/11
Vaccinating Cattle to Protect Human Health a Topic for First International One Health Congress

10/02/11
Bioniche Life Sciences Inc. Reports Fiscal 2011 Second Quarter Results

January 2011

27/01/11
Bioniche Life Sciences Inc. Securities Now Trading on the Australian Securities Exchange (ASX)

20/01/11
Bioniche Life Sciences Inc. Listing on the Australian Securities Exchange (ASX)

04/01/11
Bioniche Completes Australian Offer, Raising A$12.5 Million

03/01/11
Bioniche Announces Reorganization of Leadership Team

December 2010

21/12/10
Bioniche Animal Health and IMV Technologies Sign European Distribution Agreement

16/12/10
Bioniche Closes Canadian Portion of 20 Million Common Share Offer

14/12/10
Canadian Underwriters Exercise Over-Allotment Option as Part of Bioniche Share Offer

13/12/10
Bioniche Files Final Documentation for Canadian Portion of 20 Million Common Share Offer

10/12/10
Bioniche Prices Canadian Portion of 20 Million Common Share Offer

06/12/10
Bioniche, Through Distributor, Provides Exclusive Supply to Angus Association in Australia

November 2010

30/11/10
Bioniche Obtains Exclusive U.S. Rights to Equine Reproductive Product from CreoSalus

22/11/10
Bioniche Files Regulatory Documents for 20 Million Common Share Offer in Canada and Australia

17/11/10
Urocidin Phase III Trial Results Trigger Milestone Payment to Bioniche from Endo

15/11/10
Bioniche Presents at U.S. Animal Health Association Committee on Food & Feed Safety

10/11/10
Bioniche Reports Fiscal 2011 First Quarter Results

October 2010

28/10/10
Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada for a Second Time

19/10/10
Fonds de solidarité FTQ Converting
Remainder of its Preferred Shares in Bioniche

18/10/10
Bioniche Scientists Present at Modern Vaccine & Adjuvant Formulation Conference in France

September 2010

27/09/10
Bioniche Experiences Increased Trading Activity

10/09/10
Bioniche Reports Fiscal 2010 Year-End Results

August 2010

25/08/10
Bioniche & University of Ottawa Sign Exclusive Global License Agreement for Natural Health Technology

20/08/10
Additional Phase III Clinical Trial with UrocidinTM Expected to Commence in 2010

June 2010

23/06/10
Bioniche & Trophogen Sign Exclusive Global Veterinary License Agreement for Superagonist Hormone Technology Platform

17/06/10
Bioniche Strengthens its International Patent Portfolio for its MCC & Oligonucleotide Technology Platforms

02/06/10
Bioniche Animal Health Partners with Bayer Australia to Distribute Livestock Product Line

May 2010

17/05/10
Bioniche Recognizes 10th Anniversary of Walkerton, Ontario Water Contamination Tragedy

12/05/10
Bioniche Reports Fiscal 2010 Third Quarter Results

April 2010

19/04/10
Bioniche Receives FedDev Ontario Investment to Support Fermentation Scale-Up for New Vaccine Manufacturing Centre

March 2010

16/03/10
Canadian Cattle Producers Willing to Make Changes to Prevent E. coli O157 Contamination on their Farms

February 2010

12/02/10
Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights

10/02/10
Bioniche Reports Fiscal 2010 Second Quarter Results

January 2010

29/01/10
Bioniche E. coli O157 Vaccine Recognized in Prestigious Scientific Journal

November 2009

25/11/09
Bioniche Strengthens the International Patent Portfolio for its MCC Technology Platform

06/11/09
Bioniche Reports Fiscal 2010 First Quarter Results And Achievement of First Milestone Under Licensing Agreement

September 2009

21/09/09
Bioniche Reports Fiscal 2009 Year-End Results

August 2009

24/08/09
Bioniche Phase III Clinical Trial with Urocidin™ Given Continued Green Light by DMC

05/08/09
Bioniche Announces Resignation of its CFO

July 2009

20/07/09
Bioniche Repays Revolving Credit Facility

17/07/09
EconicheTM Vaccine Efficacy Summarized in July Issue of Foodborne Pathogens and Disease

10/07/09
Bioniche Life Sciences Inc. and Endo Pharmaceuticals Inc. Sign Licensing Agreement for UrocidinTM

June 2009

22/06/09
Bioniche Provides a Corporate Update

May 2009

28/05/09
Bioniche Represented at House of Commons Sub-Committee on Food Safety

22/05/09
Bioniche Phase III Clinical Trial with Urocidin™ Progressing Well

06/05/09
Bioniche Reports Fiscal 2009 Third Quarter

April 2009

27/04/09
Bioniche Provides a Corporate Update

March 2009

31/03/09
Bioniche Completes Recruitment in First Phase III Clinical Trial with UrocidinTM

13/03/09
EconicheTM Vaccine Shows 92% Reduction in Colonization of E. coli O157 in Vaccinated Cattle

02/03/09
Bioniche Revolving Credit Facility Maturity Date Amended

February 2009

18/02/09
Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology

17/02/09
Bioniche Warrants’ Expiration Date to be Extended

06/02/09
Bioniche Reports Fiscal 2009 Second Quarter

03/02/09
Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable

January 2009

14/01/09
Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada

November 2008

24/11/08
Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile

17/11/08
Update on Bioniche Phase III Clinical Trial in Bladder Cancer

07/11/08
Bioniche Reports Fiscal 2009 First Quarter

October 2008

27/10/08
World’s First Cattle Vaccine to Reduce E. coli O157 Threat Receives Full Licensing Approval in Canada

17/10/08
E. coli O157 Vaccine Efficacy Reinforced by Study Published in Foodborne Pathogens and Disease

September 2008

24/09/08
Canadian Regulator Recognizes Efficacy and Safety of Bioniche E. coli O157 Cattle Vaccine

19/09/08
Bioniche Reports Fiscal 2008 Year-End Results

09/09/08
Bioniche Allows Conversion of Portion of Revolving Credit Facility

August 2008

25/08/08
Bioniche Animal Health Immunotherapy Now Listed as “Organic” for Use in Cattle

18/08/08
Bioniche Phase III Clinical Trial in Bladder Cancer Progressing Well

July 2008

10/07/08
Bioniche Presents E. coli O157:H7 Vaccine Data to World Buiatrics Congress in Budapest, Hungary

June 2008

27/06/08
Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference

25/06/08
Bioniche Secures Final Financing to Scale-up E. coli O157:H7 Vaccine Production

17/06/08
Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia.

May 2008

23/05/08
Bioniche Presents Pre-Clinical Research at Two International Conferences

13/05/08
Bioniche Updates re: Mycobacterial Cell Wall Technology Platform

09/05/08
Bioniche Reports Fiscal 2008 Third Quarter

April 2008

21/04/08
Bioniche Appoints U.S. President of Food Safety

18/04/08
Bioniche Reports the Passing of its Board Chair

March 2008

27/03/08
Bioniche Converts a Portion of its Debt to Equity

04/03/08
Bioniche Receives Fast track Designation for First-Line Bladder Cancer Therapy

February 2008

13/02/08
Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin™

12/02/08
Bioniche Reports Fiscal 2008 Second Quarter

08/02/08
Bioniche Receives $5 Million Capital Financing Support to Scale-up E. coli O157:H7 Vaccine Production

05/02/08
USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine

December 2007

21/12/07
Bioniche Amends Terms of Convertible Debt with Laurus Master Funds

20/12/07
Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario

18/12/07
Bioniche Receives $10 Million of Provincial Government Support to Scale-up Vaccine Production in Ontario

17/12/07
Announcement Planned by Ontario Ministry of Economic Development and Trade

04/12/07
Bioniche Recognized as One of the Top 10 Life Science Companies in Canada

November 2007

15/11/07
Bioniche Presents at Annual Convention of Canadian Association of Fairs & Exhibitions

13/11/07
Journal of Food Protection Publishes Two Articles on E. coli O157:H7 Vaccine Efficacy

09/11/07
Bioniche Reports Fiscal 2008 First Quarter

06/11/07
Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference

October 2007

05/10/07
Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine

05/10/07
Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial

04/10/07
Bioniche to Present at BioContact Quebec 2007

September 2007

27/09/07
Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards

26/09/07
Bioniche Reports Fiscal 2007 Year-End Results

24/09/07
Beef Cattle Vaccinated Against E. coli O157:H7

21/09/07
Bioniche Reports Year-End Fiscal 2007 Results

10/09/07
Bioniche Reaches Special Protocol Assessment Agreement with U.S. FDA for Phase III Comparative Bladder Cancer Trial

07/09/07
Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine

06/09/07
Bioniche Responds to Australian Equine Influenza Outbreak

August 2007

24/08/07
Bioniche Ships First Order of E. coli O157:H7 Cattle Vaccine

16/08/07
Bioniche Provides Update on Refractory Bladder Cancer Trial

July 2007

30/07/07
Bioniche Lists Warrants in Connection with March 7, 2007 Offering of Units

19/07/07
Bioniche Appoints New Animal Health and Food Safety Leadership Team

18/07/07
Bioniche Appoints New Director to its Board

June 2007

06/06/07
Solidarity Fund QFL Converting 25% of its Preferred Shares in Bioniche Life Sciences

May 2007

22/05/07
Data Shows Bioniche Proprietary MCC Technology Effective in Inducing Anticancer Activity in 3 Hours

04/05/07
Bioniche Reports Third Quarter Results for Fiscal 2007

01/05/07
Bioniche E. coli O157:H7 Vaccine Discussed at 4th International Conference on Vaccines for Enteric Diseases

April 2007

18/04/07
Bioniche Eliminates Convertible Debt with Laurus Master Funds

16/04/07
Bioniche Presents Additional Data on the Anticancer Activity of MCC Against Peritoneal Carcinomatosis

03/04/07
Non-Antibiotic Treatment for Equine Endometritis Study Data Published in International Peer-Reviewed Journal

March 2007

30/03/07
Bioniche Recognized with Québec Biotechnology Award

29/03/07
Bioniche and Technology Partnerships Canada Amend Agreement on MCC Research Project

13/03/07
Bioniche Closes C$17.5 Million Equity Financing

02/03/07
Bioniche Files Final Short-Form Prospectus for Offering of Units

February 2007

09/02/07
Bioniche Files Preliminary Short-Form Prospectus for Offering of Units

02/02/07
Bioniche Reports Second Quarter Results for Fiscal 2007

January 2007

12/01/07
Bioniche Further Pays Down Debt with Laurus Master Funds

10/01/07
Canadian Research Collaboration Produces World's First Food Safety Vaccine: Against E. coli 0157:H7

December 2006

22/12/06
Bioniche E. coli O157:H7 Cattle Vaccine Authorized for Field Use in Canada

22/12/06
Bioniche Further Pays Down Debt

15/12/06
Bioniche Life Sciences Experiences Significant Trading Volume Following Progress Update on E. coli O157:H7 Cattle Vaccine Canadian Regulatory Status

08/12/06
Bioniche Life Sciences Clears Path for Priority Review of its E. coli O157:H7 Cattle Vaccine in Canada

08/12/06
Bioniche Completes Sale of Two Remaining Assets Associated with Irish Pharma Group

06/12/06
Bioniche Life Sciences' E. coli O157:H7 Cattle Vaccine Data Presented at Two International Symposia

November 2006

10/11/06
Bioniche Reports First Quarter Results for Fiscal 2007

08/11/06
First Patient Treated in Bioniche Phase III Refractory Bladder Cancer Trial

07/11/06
Bioniche Plans to Liquidate Two Remaining Assets Associated with Irish Pharma Group

02/11/06
Bioniche Expands Patent Portfolio with Three New Patents

October 2006

31/10/06
Bioniche to Present at Rodman & Renshaw 8th Annual Healthcare Conference

02/10/06
Bioniche Board Approves a Shareholders Rights Plan

September 2006

29/09/06
Bioniche Life Sciences Inc. Re-Files its 2005 MD&A and Certificates

28/09/06
Bioniche Reports Fiscal Year-End Results

22/09/06
Update for Bioniche Year-End Fiscal 2006 Call/Cast Per CNW Group

15/09/06
New Date for Bioniche Year-End Fiscal 2006 Call/Cast

11/09/06
Bioniche Reports Year-End Fiscal 2006 Results

June 2006

29/06/06
Bioniche Presents Additional Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Human Bladder Cancer Cells

27/06/06
Cameron Groome Joins Bioniche as Executive Vice-President, Corporate & Strategic Development

05/06/06
Counterfeit Product Linked to Death of Ontario Horse

May 2006

24/05/06
Mycobacterial Cell Wall-DNA Complex (MCC) Demonstrates Anticancer Activity in an Animal Model of Colon Cancer

23/05/06
Bioniche Closes Sale of its Proprietary Cystitis Product

09/05/06
Bioniche Third Quarter Results Correction

05/05/06
Bioniche Reports Third Quarter Results for Fiscal 2006

04/05/06
U.S. FDA Grants Fast Track Designation for Bioniche Bladder Cancer Product

03/05/06
Bioniche Sells Proprietary Cystitis Product for $10 Million Cdn.

02/05/06
Media Advisory - Bioniche Reports Third Quarter Results for Fiscal 2006

April 2006

03/04/06
Bioniche Receives FDA Approval to Proceed with Phase III Bladder Cancer Trials

March 2006

27/03/06
Bioniche to Host Bladder Cancer Roundtable

22/03/06
Updates on MCC Phase III Bladder Cancer Study and E. coli O157:H7 Cattle Vaccine Regulatory Progress

13/03/06
Bioniche Granted First Major Composition Patent for Oligonucleotide Technology

February 2006

08/02/06
Bioniche Reports Second Quarter Results for Fiscal 2006

07/02/06
U.S. FDA Accepts Part One of Bioniche Program for Phase III Clinical Trials with MCC for Bladder Cancer

02/02/06
Media Advisory - Bioniche Reports Second Quarter Results for Fiscal 2006

01/02/06
Bioniche and RoundTable Healthcare Partners Close Sale of Bioniche Pharma Group Ltd.

January 2006

12/01/06
Bioniche Signs Definitive Purchase Agreement for Sale of Pharma Group to RoundTable Healthcare Partners

December 2005

09/12/05
Bioniche Completes Private Financing

November 2005

04/11/05
Bioniche Reports First Quarter Results for Fiscal 2006

01/11/05
Bioniche Annual Meeting Web Cast and First Quarter Results for Fiscal 2006

October 2005

28/10/05
Bioniche Clarifies Terms of Pharma Group Sale and Private Placement

18/10/05
Bioniche Pharma Group and AngioDynamics Sign Exclusive Distribution Agreement for Sotradecol(R) Injection

14/10/05
Bioniche Discussing Potential Private Placement

05/10/05
Bioniche and ICC Private Equity Fund Agree to Sell Bioniche Pharma Group to RoundTable Healthcare Partners

04/10/05
Bioniche Retains Blackmont Capital to Assist in the Sale of its Pharma Business Unit

September 2005

29/09/05
Bioniche Reports Fiscal Year-End Results and Unveils Plans to Convert Business Unit into Cash

26/09/05
Bioniche in Good Standing with Technology Partnerships Canada (TPC)

20/09/05
New Date/Time for Bioniche Fiscal 2005 Year-End Call/Cast

15/09/05
Bioniche Reports Year-End Fiscal 2005 Results

July 2005

14/07/05
Bioniche Launches Sotradecol® Injection for Varicose Veins in U.S. Market

12/07/05
Bioniche Reports Positive News from BetacTM Product Recall Investigation

June 2005

20/06/05
Bioniche Life Sciences Retains GCI Group as Strategic Investor Relations Counsel

17/06/05
Bioniche Issues Recall of BetacTM

16/06/05
Bioniche Presents Data on Anticancer Activity of Mycobacterial Cell Wall-DNA Complex (MCC) Against Peritoneal (Colon) Cancer

13/06/05
Bioniche Appoints New Chief Medical Officer to Advance Clinical Trials

03/06/05
New Studies Demonstrate Immunomodulatory Activity of Bioniche Technology in Dogs

03/06/05
New Studies Demonstrate Immunomodulatory Activity of Bioniche Technology in Dogs

01/06/05
Bioniche Pharma Group and Grünenthal Sign Exclusive Agreement for Distribution of Suplasyn®

May 2005

26/05/05
Bioniche Granted European Patent for Mycobacterial Cell Wall-DNA Complex (MCC) as Prostate Cancer Treatment

24/05/05
Bioniche Mycobacterial Cell Wall Extract (MCWE) Granted New Patent for Production Performance in Animals

17/05/05
Bioniche Granted Additional Patent for Mycobacterial Cell Wall Technology

13/05/05
Bioniche Announces Change in Board of Directors Composition

09/05/05
Bioniche Reports Third Quarter Fiscal 2005 Results

04/05/05
Bioniche to Present at Rodman & Renshaw

03/05/05
Bioniche Reports Third Quarter Results for Fiscal 2005

April 2005

18/04/05
Bioniche Presents Data on Prevention and Management of Urinary Tract Infections Using Cystistat®

March 2005

29/03/05
Bioniche Granted European Patent for MCC in Bladder Cancer

22/03/05
Bioniche Presents Further Data on Mycobacterial Cell Wall-DNA Complex (MCC) at European Association of Urology 20th Congress

14/03/05
Further Research Studies Support E. coli Cattle Vaccine Efficacy

07/03/05
Research Shows Promise for Easy, Effective Management of Sow Breeding

February 2005

10/02/05
Bioniche Reports Second Quarter Fiscal 2005 Results

09/02/05
Bioniche Reports Second Quarter Results for Fiscal 2005

January 2005

28/01/05
Bioniche to Submit Additional Safety Data for its E. coli Vaccine

21/01/05
Bioniche Receives Authorization to Market Folltropin®-V in Additional EU Countries

December 2004

23/12/04
Bioniche Animal Health Appoints New Leaders of European and Australian/Asian Operations

06/12/04
Senior Personnel Change at Bioniche

03/12/04
Livestock Revolution in Global Agriculture

November 2004

29/11/04
New Treatment for Equine Endometritis Given USDA Approval

22/11/04
FDA Approves Bioniche Pharma ANDA for Sotradecol Injection for the Treatment of Varicose Veins

18/11/04
New Data Confirms Unique Anticancer Activity Profile

09/11/04
Bioniche Discusses Further Details of the Phase III Clinical Trial with Urocidin for the Treatment of Bladder Cancer

09/11/04
Bioniche Revenues Increase in First Quarter of Fiscal 2005

08/11/04
New Studies Demonstrate Anti-Cancer Activity of Bioniche Technology Against Canine Cancer

04/11/04
Bioniche Reports First Quarter Results for Fiscal 2005

October 2004

28/10/04
Investment in Bioniche Life Sciences Inc.The Solidarity Fund QFL will invest $10 M and the Bio-Food Investment Fund $2 Mac

20/10/04
Bioniche Annual Report Correction

15/10/04
Industrial Research Chairs in Food Safety Filled

06/10/04
Bioniche Expands its Intellectual Property Portfolio

September 2004

23/09/04
Bioniche Presents Data on Cystistat and Launches Product Web Site at Inaugural Multinational Interstitial Cystitis Association Annual Meeting

21/09/04
Bioniche Reports Year-End Fiscal 2004 Results

20/09/04
Bioniche Appoints a Chief Operating Officer

15/09/04
Bioniche Reports Year-End Fiscal 2004 Results

August 2004

26/08/04
Bioniche Ranked Among the Top 100 Global Biotechnology Companies by Med Ad News

06/08/04
Mycobacterial Cell Wall Formulation Shows Promise in Treating Equine Endometritis

03/08/04
Bomac Laboratories Ltd. to Distribute Bioniche Cue-Mate® Technology in New Zealand

July 2004

22/07/04
Bioniche Presents Pre-Clinical Data on Anti-Cancer Agents and Immunomodulatory Molecules at International Congress of Immunology

June 2004

21/06/04
Bioniche Commences Sales of Cue-Mate® Animal Reproductive Technology in Australian Cattle Market

18/06/04
Bioniche Receives Approval For New Animal Health Product Indication

14/06/04
Pharmacoeconomic Study into Use of Suplasyn® Demonstrates Reduced Pain and Cost-Effectiveness in Treatment of Patients with Osteoarthritis of the Knee

14/06/04
Bioniche Serves Community Needs Through New Pet Loss Program

10/06/04
Bioniche Presents Positive Data on Anti-Cancer Activity of MCC at 22nd Annual Meeting of American College of Veterinary Internal Medicine

08/06/04
Bioniche Ranked Among Canada’s Top 100 Fastest-Growing Companies by PROFIT Magazine

01/06/04
Bioniche Retains The Anne McBride Company Inc.

May 2004

21/05/04
Bioniche’s Pharmaceutical Business Unit Raises 10.8 Million Euro for Expansion of Manufacturing Facilities

20/05/04
Bioniche Presents Bladder Cancer Clinical Trial and Research Data to American Urological Association Annual Meeting

14/05/04
Bioniche Reports Third Quarter Fiscal 2004 Results

12/05/04
Bioniche Reports Third Quarter Fiscal 2004 Results Web Cast

12/05/04
Bioniche E. coli 0157 Vaccine Shows Further Promise

April 2004

19/04/04
Bioniche Acquires Cue-Mate® Reproductive Technology From Pfizer

March 2004

29/03/04
Bioniche Announces Results of Phase I Prostate Cancer Study

February 2004

17/02/04
Bioniche Life Sciences Completes $10,000,000 Financing

13/02/04
Bioniche Reports Second Quarter 2004 Financial Results

05/02/04
Bioniche Enters Into Agreement For $10,000,000 Financing

January 2004

10/01/04
Bioniche Life Sciences and AB Technology Sign Purchase Agreement


Newsroom

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Human Health
One Health

Copyright 2004, Bioniche Life Sciences Inc. All rights reserved  |  Legal Disclaimer  |  Privacy Policy